The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Tuberculosis

Tuberculosis

Tuberculosis is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis.
It primarily affects the lungs, but can also impact other organs.
Symptoms may include cough, fever, weight loss, and fatigue.
Effective treatments are available, but the disease remains a major global health challenge, particularly in developing countries.
Ongoing research aims to improve diagnosis, treatment, and prevention strategies for this complex and multifaceted condition.

Most cited protocols related to «Tuberculosis»

We combined the entire cohort of self-identified European American individuals identified across the five eMERGE sites (n = 13,835 individuals) into one analysis. To define diseases, we queried all ICD9 codes from the respective EMRs from the five eMERGE sites. The PheWAS software then used these ICD9 codes to classify each person as having one of the 1,358 possible clinical phenotypes belonging to >25 patients in the populations (as noted above). For each disease, the PheWAS code defined relevant control groups for each disease or finding, such that patients with related diseases do not serve as controls for that disease (e.g., a patient with Graves disease cannot serve as a control for an analysis of thyroiditis).
We have previously found that the positive predictive value for some algorithms to establish a diagnosis from EMR data is improved by requiring the presence of multiple instances of disease-associated ICD9 codes44 (link). For example, to be considered a case for tuberculosis, a patient is required to have at least two ICD9 codes in the ranges of 10–18 (tuberculosis infections of different sites), 137 (late effects of tuberculosis) or V12.01 (personal history of tuberculosis). Accordingly, for the present study, we used a threshold of relevant ICD9 codes on two distinct days to establish that person as a “case” for a given phenotype. Controls are patients without any ICD9 codes in the corresponding control range; thus, patients with a single ICD9 case code are excluded for the analysis as neither a case nor a control. Each SNP-phenotype association test was run independently with PLINK43 (link), using logistic regression adjusted for age, gender, site (e.g., Vanderbilt, Marshfield Clinic), and the first three principal components as calculated by EIGENSTRAT, using ancestry informative markers as above41 (link). Analysis was performed assuming an additive genetic model. These data were aggregated and analyzed using Perl scripts and the R statistical package.
Publication 2013
Diagnosis Europeans Graves Disease Patients Phenotype Population Group Thyroiditis Tuberculosis
The GBD study attributes each death to a single underlying cause that began the series of events leading to death, in accordance with ICD principles. The GBD study organises causes of death in a hierarchical list containing four levels (appendix 1 section 7). At the highest level (Level 1), all disease burden is divided among three mutually exclusive and collectively exhaustive categories: communicable, maternal, neonatal, and nutritional (CMNN) diseases; non-communicable diseases (NCDs); and injuries. Level 2 distinguishes these Level 1 categories into 21 cause groups, such as cardiovascular diseases; diarrhoeal diseases, lower respiratory infections (LRIs), and other common infectious diseases; or transport injuries. Level 3 disaggregates these causes further; in most cases this disaggregation represents the finest level of detail by cause, such as stroke, ischaemic heart disease, or road injuries. Where data are sufficiently available or specific policy relevance has been sought, selected causes are further disaggregated at Level 4, such as drug-susceptible tuberculosis, multidrug-resistant tuberculosis without extensive drug resistance, and extensively drug-resistant tuberculosis. For GBD 2017, the cause hierarchy was further refined to separately estimate causes with substantial policy interest or high levels of burden. Specific changes included separate estimation of non-rheumatic calcific aortic and degenerative mitral valve diseases, and myelodysplastic, myeloproliferative, and other haemopoietic neoplasms, resulting in a reduction in the estimates of some residual causes. Disaggregation of residual causes also allowed separate estimation of type 1 and type 2 diabetes, chronic kidney disease due to type 1 and type 2 diabetes, poisoning by carbon monoxide, liver cancer due to non-alcoholic steatohepatitis (NASH), subarachnoid haemorrhage, ectopic pregnancy, and invasive non-typhoidal salmonella. Maternal and neonatal disorders, previously estimated as separate cause groupings at Level 2 of the hierarchy, were estimated for GBD 2017 at Level 3 of the hierarchy, and then aggregated up to Level 2 to better capture the epidemiological connections and linked burden between them. The complete hierarchy of causes included in GBD 2017 and their corresponding ICD9 and ICD10 codes are described in appendix 1 (section 7).
Full text: Click here
Publication 2018
Aorta Cancer of Liver Carbon Monoxide Poisoning Cardiovascular Diseases Cerebrovascular Accident Chronic Kidney Diseases Communicable Diseases Diabetes Mellitus, Non-Insulin-Dependent Diarrhea Ectopic Pregnancy Extensively Drug-Resistant Tuberculosis Hematopoietic Neoplasms Infant, Newborn Injuries Mitral Valve Mothers Myocardial Ischemia Neonatal Diseases Nonalcoholic Steatohepatitis Noncommunicable Diseases Nutrition Disorders Pharmaceutical Preparations Resistance, Drug Respiratory Tract Infections Salmonella Subarachnoid Hemorrhage Tuberculosis Tuberculosis, Multidrug-Resistant Typhoid Fever
We first construct the n × m genotype matrix X, by centering and scaling the allele counts for each SNP according to Xi,j = (Si,j−2fj) × [2fj (1−fj)]α/2, where fj = ΣiSi,j/2n. If wj and rj denote the LD weight9 (link) and information score for SNP j, then the LDAK Model for estimating SNP heritability hSNP2=σg2/(σg2+σe2) is: Yi=k=1pθkZi,k+j=1mβjXi,j+ei,withβj(0,rjwjσg2/W),ei(0,σe2)andW=j=1mrjwj[2fj(1fj)]1+α.
θk denotes the fixed-effect coefficient for the kth covariate, βj and ei are random-effects indicating the effect size of SNP j and the noise component for Individual i, while σg2 and σe2 are interpreted as genetic and environmental variances, respectively. Note that the introduction of rj is an addition to the model we proposed in 2012.9 (link)
Model (2) is equivalent to assuming:44 , 45 (link)
Y(Zθ,Kσg2+Iσe2),withK=XΩXTW, where I is an n × n identity matrix and Ω denotes a diagonal matrix with diagonal entries (r1w1, …, rmwm). The kinship matrix K, also referred to as a genetic relationship matrix (GRM)1 (link) or genomic similarity matrix (GSM),46 (link) consists of average allelic correlations across the SNPs (adjusted for LD and genotype certainty). Model (3) is typically solved using REstricted Maximum Likelihood (REML), which returns estimates of θ1, …, θp, σg2 and σe2. 12
The heritability of SNP j can be estimated by hj2=βj2Var(Xj)/Var(Y), which under Model (2), and assuming Hardy-Weinberg Equilibrium,47 (link), 48 has expectation 𝔼[hj2]=𝔼[βj2]×Var(Xj)Var(Y)=rjwjσg2/W×[2fi(1fj)]1+αVar(Y). If P1 and P2 index two sets of SNPs of size |P1| and |P2|, then under the LDAK Model, they are expected to contribute heritability in the ratio W1 : W2, where Wl = Σj∈Plrjwj [2fj (1−fj)]1+α. The GCTA Model corresponds to setting wj = rj = 1, in which case Wl = ΣjPl [2fj (1−fj)]1+α. Most applications of GCTA have further assumed α = −1, so that Wl = |Pl|, which corresponds to the assumption that SNP sets are expected to contribute heritability proportional to the number of SNPs they contain.
Model (2) assumes that all effect-sizes can be described by a single prior distribution. This assumption is relaxed by SNP partitioning. Suppose that the SNPs are divided into tranches P1, …, PL of sizes |P1|, …, |PL|; typically these will partition the genome, so that each SNP appears in exactly one tranche and Σl |Pl| = m, but this is not required. This correspond to generalizing Model (2), so that SNPs in Tranche l have effect-size prior distribution βj(0,rjwjσl2/Wl). Letting Σ=σ12++σL2, then hSNP2=Σ/(Σ+σe2), while σl2/Σ represents the contribution to hSNP2 of SNPs in Tranche l. This model can equivalently be expressed as Y(Zθ,K1σ12++KLσL2+Iσe2), where Kl represents allele correlations across the SNPs in Tranche l.
For analyses under the LDAK Model, we used LDAK v.5; for analyses under the GCTA Model, we used GCTA v.1.26. For about a third of GCTA-LDMS analyses, the GCTA REML solver failed with the error “information matrix is not invertible,” in which case we rerun using LDAK (while the GCTA and LDAK solvers are both based on Average Information REML,28 (link), 49 (link) subtle differences mean that when using a large number of tranches, one might complete while the other fails). For the few occasions when both solvers failed, we instead used “GCTA-LD” (i.e., SNPs divided only by LD, rather than by LD and MAF), which we found gave very similar results to GCTA-LDMS for traits where both completed (Supplementary Fig. 7). For diseases, we converted estimates of hSNP2 to the liability scale based on the observed case-control ratio and assumed prevalence.26 (link), 27 (link) In general, we copied the prevalences used by previous studies; however for tuberculosis, where no previous estimate of hSNP2 is available, we derived an estimate of prevalence from World Health Organization data50 (see Supplementary Note).
Publication 2017
Alleles Genome Genotype Iodine Reproduction Single Nucleotide Polymorphism Tuberculosis
To evaluate RATT, we assessed its performance using manually annotated genomes. The M. tuberculosis strain H37Rv (NCBI:AL123456) was used to annotate the genome of strain F11 using the ‘Strain’ comparison option. Results were compared with the existing annotation of F11 (NCBI:CP000717). In addition, the annotation of P. chabaudi was mapped to the P. berghei version 9 genome using the ‘Species’ comparison option. The P. chabaudi/P. berghei dataset can be downloaded from http://ratt.sourceforge.net/Chab_berg.zip. The files relating to the transfer of annotation between P. berghei assemblies can be found at http://ratt.sourceforge.net/Berg_berg.zip. The transfer was performed using the ‘Assembly.Repetitive’ parameters, and the results are included in the latest GeneDB version (http://www.genedb.org).
Although, direct benchmarking was not possible because RATT presents a new strategy, we ran Glimmer3—a popular ab initio gene predictor—on the tuberculosis dataset as a comparator. Particular attention was given to the number of CDSs transferred or predicted, and whether their boundaries coincided with curated models. After running RATT on each of the three datasets, the transferred annotations were manually checked in Artemis and ACT.
Publication 2011
Attention Genes, vif Genome Mycobacterium tuberculosis H37Rv Strains Triglyceride Storage Disease with Ichthyosis Tuberculosis
Drawing from methods established in GBD 2015,20 (link) our analysis involved four steps: mapping the Nolte and McKee cause list to GBD causes; constructing MIRs for cancers and risk-standardising non-cancer deaths to remove variations in mortality not directly amenable to health care; calculating the HAQ Index on the basis of principal components analysis (PCA), providing an overall score of personal health-care access and quality on a scale of 0–100; and examining associations between national HAQ Index scores and potential correlates of performance.
Our study draws from GBD 2016 results,31 (link), 32 (link), 33 (link) which entail several improvements since GBD 2015, including 169 new country-years of vital registration data, 528 new cancer-registry years with a total of 92 countries' cancer registries,31 (link) five new risk factors,32 (link) and cause-specific mortality modelling updates (eg, cancers, tuberculosis).31 (link) Further information can be found in the appendix (pp 12–89) and the GBD 2016 capstone series.31 (link), 32 (link), 33 (link)
In addition to national and aggregated HAQ Index results, we report estimates at the subnational level for Brazil (26 states and the Federal District), China (33 provinces and special administrative regions), England (nine regions and 150 local government areas), India (31 states and union territories), Japan (47 prefectures), Mexico (32 states), and the USA (50 states and the District of Columbia).
As with all GBD revisions, GBD 2016 HAQ Index estimates for the full time series published here supersede previous iterations. This analysis complies with the Guidelines for Accurate and Transparent Health Estimates Reporting (GATHER);34 (link) additional information is found in the appendix (pp 5–7).
Full text: Click here
Publication 2018
Malignant Neoplasms Tuberculosis

Most recents protocols related to «Tuberculosis»

The study protocol was approved by the institutional review board at each site. Informed consent was obtained from all patients. We retrospectively documented the data of ASD patients in two hospitals from January 2018 to December 2019, aiming to have a minimum follow-up of 24 months. All of those patients had undergone the procedure of long-fusion (≥ 5 vertebras) with instrumentations by posterior-only approach.
General inclusion criteria for this study were as follows:

Age ≥ 45 years;

Those radiographic parameters met the criteria at least one of the followings: a, coronal curvature ≥ 20°; b, SVA ≥ 5 cm; c, PT ≥ 25°; d, TK ≥ 60° [16 (link), 17 (link)].

The research data before and after surgery, including demographics, surgical and radiographic parameters, were integrated.

The follow-up duration ≥ 24 months.

Those having 1) prior spinal surgeries, 2) history of spinal tumor, 3) history of spinal infection such as tuberculosis, 4) ankylosing spondylitis, 5) any hip disorders, or 6) the differences between two lower extremities ≥ 2 cm were excluded.
In this current study, proximal junctional failure (PJF) was defined as fractures or subluxations happening in the UIV and/or UIV + 1; pedicle screw loosening, dislodgment, or even pullout from the UIV [18 (link)]. Demographics (age, gender, and BMI) and surgical data involving UIV, lower instrumented vertebra (LIV), and fixed segments (FS) were reviewed and documented. Postoperatively, follow-up time and PJF-free survival time after surgery were documented. Radiographs at the pre-operation, the immediate post-operation, and the final follow-up were collected.
Full text: Click here
Publication 2023
Ankylosing Spondylitis Ethics Committees, Research Fracture, Bone Gender Infection Joint Subluxations Lower Extremity Patients Pedicle Screws Spinal Neoplasms Tuberculosis Vertebra X-Rays, Diagnostic
The EMRMS was established in November, 2016 to assist rheumatologists in conducting ASDAS assessments and comprehensively evaluating clinical outcomes in all patients with AS attending TCVGH. The EMRMS database contains information necessary to determite ASDAS, including CRP, level and erythrocyte sedimentation rate [ESR], patient comorbidities, patient history, and family history. The reliability and validity of the data have been verified14 (link).Patients with AS were consecutively enrolled in the TCVGH-AS cohort after they received a confirmed AS diagnosis from a TCVGH rheumatologist according to the 1984 modified New York criteria10 (link). The CRP and ESR data were automatically uploaded to the TCVGH healthcare information system (HIS) to reduce human error. The baseline information, which was collected by trained nurses during the initial visit, including clinical characteristics, onset age, comorbidities at presentation (hypertension, diabetes mellitus, hyperlipidemia, hepatitis B, hepatitis C, renal insufficiency, gout, coronary artery disease, stroke, periodontal disease, osteoporosis, and tuberculosis history), periarticular extraspinal features (synovitis, enthesitis, and dactylitis) and nonarticular manifestations (psoriasis, uveitis, and IBD), family history of autoimmune disease, and patient history of arthropathy, obtained through standardized questionnaires and worksheets to ensure reproducibility and adherence to good laboratory practice. The rheumatologist in charge then confirmed patients’ clinical characteristics, and nurses assisted the patients with AS to complete the self-assessment questionnaires for disease evaluation. The following measures were used: global assessment of disease activity on a numerical rating scale (NRS) of 0–10, back pain on an NRS of 0–10, duration of morning stiffness on an NRS of 0–10, and peripheral pain or swelling on an NRS of 0–10. Before every 3-month visiting clinic, the patient would first to have blood examination. Blood reports can be uploaded to EMRMS through the HIS system, trained nurses assist patient fills out the questionnaire on EMRMS, the assessment of disease activity completed before visiting the doctor. All laboratory data, including CRP and ESR, have been uploaded to the HIS. The IT at TCVGH help "feed-forward" the patient reported outcomes to HIS, and do the auto-calculation of ASDAS-ESR, ASDAS-CRP using the ESR, CRP data in HIS, then "feed-back" these data to both HIS and EMRMS, showing the data on the summary overview "dashboard" in the EMRMS, which was shown both in HIS and the devices (iPAD handled by a nurse in charge and smartphones of patients with AS).
Full text: Click here
Publication 2023
Arthropathy Autoimmune Diseases Back Pain BLOOD Cerebrovascular Accident Charge Nurses Coronary Artery Disease Diabetes Mellitus Diagnosis Gout Hepatitis B Hepatitis C virus High Blood Pressures Homo sapiens Hyperlipidemia Medical Devices Nurses Osteoporosis Pain Patients Periodontal Diseases Physicians Psoriasis Renal Insufficiency Rheumatologist Sedimentation Rates, Erythrocyte Self-Assessment Synovitis Tuberculosis Uveitis
The diagnosis of anal fistula is based on the German S3 guidelines: anal abscess and fistula (23 (link)). All patients were diagnosed with anal fistula by anal finger examination, anoscope examination, radiographic examination (including rectal endoluminal ultrasound, pelvic CT, or MRI), or intraoperative probe/methylene blue staining, and the number of internal orifices was counted by these techniques. The diagnostic criteria for T2DM were based on the latest Chinese guidelines for the prevention and treatment of T2DM set by the Chinese Diabetes Society (24 (link), 25 (link)). And the diagnosis was assigned by an endocrinologist. Relevant data were collected on the cases, including demographic characteristics, clinical features, laboratory and ancillary tests at admission, anal fistula-related information (e.g., previous surgical history, anal fistula types, number of internal orifices, etc.), pre- and post-surgical treatments, and surgical modalities. Non-healing (refractory) group refers to trauma that cannot be repaired in time with conventional therapy or wounds that can not achieve functional recovery and anatomical integrity (26 (link)). The last routine dressing change time in the outpatient clinic was collected as the outcome indicator. Judged by the specialist anorectologist and the definition of the relevant literature, patients were divided into the non-healing (refractory) group or healing group according to whether its recovery period is longer than 35 days (27 (link)–29 (link)).
Among the underlying diseases, hypertensive disease and non-alcoholic fatty liver diseases are listed independently. Chronic cardiovascular diseases included coronary atherosclerotic heart disease and lacunar cerebral infarction. Chronic lung diseases included tuberculosis, chronic obstructive pulmonary disease, and chronic pulmonary heart disease. Chronic liver diseases included chronic viral hepatitis B, cirrhosis of the liver, hepatic hemangioma, etc.
Full text: Click here
Publication 2023
Abscess Anal Fistula Anus Cardiovascular Diseases Cardiovascular System Chinese Chronic Obstructive Airway Disease Coronary Arteriosclerosis Cor Pulmonale Diabetes Mellitus Diagnosis Disease, Chronic Endocrinologists Fingers Fistula Heart Hemangioma Hepatitis B, Chronic High Blood Pressures Hospital Admission Tests Liver Liver Cirrhosis Liver Diseases Lung Lung Diseases Methylene Blue Non-alcoholic Fatty Liver Disease Operative Surgical Procedures Patients Pelvis Recovery of Function Rectum Stroke, Lacunar Therapeutics Tuberculosis Ultrasonics Wounds Wounds and Injuries X-Rays, Diagnostic
We performed a systematic search for cohorts from the Gene Expression Omnibus (GEO) (Edgar et al. 2002 (link)) database satisfying the following inclusion criteria: (i) cohorts with bacterial infections or viral infections; (ii) cohorts with hospitalization and clinical information; and (iii) cohorts with whole blood samples. Samples were excluded due to (i) sarcoid and cancer; (ii) unknown pathogens; and (iii) coinfection with bacteria and virus (Supplementary Fig. S1). From the 3203 samples across 16 cohorts, we filtered 2680 samples for subsequent analysis (Supplementary Fig. S1 and Table 1). Patients with Escherichia coli, methicillin-resistant Staphylococcus aureus, tuberculosis, influenza A virus subtype H1N1 etc. were included in the current study to identify bacterial infection and viral infection.
The samples of 14 cohorts in the discovery set were divided into 70% (1876) for training and 30% (804) for testing (Table 1). The training set is applied to extract biomarkers and further train classifiers while the test set is employed to evaluate the performance and determine the hyperparameters of bvnGPS. To verify the generalization ability of bvnGPS, 147 patients in GSE21802 and GSE57065 were used for external validation. To demonstrate the robustness and simplicity of the GPS procedure, no additional preprocessing was performed on the raw expression cohorts.
Full text: Click here
Publication 2023
Bacteria Bacterial Infections Biological Markers Blood Coinfection Escherichia coli Gene Expression Generalization, Psychological Hospitalization Influenza A virus Malignant Neoplasms Methicillin-Resistant Staphylococcus aureus Pathogenicity Patients Sarcoidosis Tuberculosis Virus Virus Diseases
The patient population for this study included adults (aged ≥ 18 years) with moderate-to-severe HS. Eligible patients were required to be diagnosed at least 1 year before the baseline visit and have a total abscess and inflammatory nodule (AN) count ≥ 5 at baseline, HS lesions in ≥ 2 distinct anatomical locations, a draining fistula count ≤ 20 at baseline, and inadequate response to oral antibiotics for the treatment of HS. Patients were ineligible to participate if they had exposure to biologic agents blocking IL-12/23, IL-23, or IL-17 within the past 6 months; prior exposure to anti-TNF therapies (except those for the treatment of HS that demonstrated inadequate response); relevant medical conditions (such as hepatitis B, hepatitis C, HIV, or tuberculosis); or if they were pregnant or breastfeeding.
Publication 2023
Abscess Adult Antibiotics, Antitubercular Biological Factors Exposure Therapy Fistula Hepatitis B Hepatitis C virus IL17A protein, human Inflammation Interleukin-12 Patients Tuberculosis

Top products related to «Tuberculosis»

Sourced in United States, Germany
The Xpert MTB/RIF is a molecular diagnostic test developed by Cepheid. It is designed to detect the presence of Mycobacterium tuberculosis (MTB) and identify resistance to the antibiotic rifampicin (RIF) directly from sputum samples. The test utilizes real-time PCR technology to provide rapid and accurate results.
Sourced in United States, Germany, Canada, United Kingdom, France, China
Middlebrook 7H9 broth is a type of culture media used for the growth and maintenance of mycobacteria, such as Mycobacterium tuberculosis. It provides essential nutrients and growth factors required by these bacteria.
Sourced in United States, Cameroon, China, Germany
The BACTEC MGIT 960 system is a fully automated mycobacterial growth indicator tube (MGIT) system designed for the detection and identification of mycobacteria in clinical specimens. The system utilizes fluorescent technology to continuously monitor for bacterial growth in liquid culture media.
Sourced in United States, Austria, Japan, Cameroon, Germany, United Kingdom, Canada, Belgium, Israel, Denmark, Australia, New Caledonia, France, Argentina, Sweden, Ireland, India
SAS version 9.4 is a statistical software package. It provides tools for data management, analysis, and reporting. The software is designed to help users extract insights from data and make informed decisions.
Sourced in United States, Canada, United Kingdom
Pertussis toxin is a protein produced by the bacterium Bordetella pertussis, the causative agent of whooping cough. It is a key virulence factor and plays a crucial role in the pathogenesis of the disease. The toxin has multiple enzymatic activities and can modulate various cellular processes.
Sourced in United States, United Kingdom, Germany, Spain
The MGIT 960 is a laboratory instrument designed for the automated detection and identification of mycobacteria in clinical samples. It utilizes liquid culture technology to rapidly detect the presence of mycobacteria, including Mycobacterium tuberculosis, in a controlled and efficient manner.
Sourced in United States, Japan, United Kingdom, Germany, Belgium, Austria, Spain, France, Denmark, Switzerland, Ireland
SPSS version 20 is a statistical software package developed by IBM. It provides a range of data analysis and management tools. The core function of SPSS version 20 is to assist users in conducting statistical analysis on data.
Sourced in United States, Germany
The BACTEC MGIT 960 is a fully automated mycobacterial detection system that utilizes liquid culture technology to facilitate the rapid detection of mycobacteria, including Mycobacterium tuberculosis, in clinical specimens. The system employs fluorescence-based technology to continuously monitor the growth of mycobacteria in culture tubes, providing timely and accurate results.
Sourced in United States, Denmark, Austria, United Kingdom
Stata version 13 is a software package designed for data analysis, statistical modeling, and visualization. It provides a comprehensive set of tools for managing, analyzing, and presenting data. Stata 13 offers a wide range of statistical methods, including regression analysis, time-series analysis, and multilevel modeling, among others. The software is suitable for use in various fields, such as economics, social sciences, and medical research.
Sourced in United States, Denmark, United Kingdom, Austria, Sweden
Stata 13 is a comprehensive, integrated statistical software package developed by StataCorp. It provides a wide range of data management, statistical analysis, and graphical capabilities. Stata 13 is designed to handle complex data structures and offers a variety of statistical methods for researchers and analysts.

More about "Tuberculosis"

Tuberculosis (TB) is a serious infectious disease caused by the bacterium Mycobacterium tuberculosis.
It primarily affects the lungs, but can also impact other organs such as the lymph nodes, spine, and brain.
The symptoms of TB may include a persistent cough, fever, weight loss, and fatigue.
While effective treatments are available, TB remains a major global health challenge, particularly in developing countries.
Various diagnostic tools are used to detect TB, including the Xpert MTB/RIF assay, which can quickly identify the presence of the TB bacteria and its resistance to the drug rifampicin.
The Middlebrook 7H9 broth is a commonly used growth medium for the cultivation of Mycobacterium tuberculosis, while the BACTEC MGIT 960 system is an automated system for the rapid detection of TB in patient samples.
Ongoing research aims to improve the diagnosis, treatment, and prevention of TB.
Statistical software such as SAS version 9.4, SPSS version 20, Stata version 13, and Stata 13 are often used to analyze data and evaluate the effectiveness of new interventions.
Additionally, the Pertussis toxin, a virulence factor produced by the bacterium Bordetella pertussis, is being studied for its potential role in the pathogenesis of TB.
By leveraging the latest advancements in technology and research, scientists and healthcare professionals are working to revolutionize the way we approach the management of this complex and multifaceted condition.
With continued efforts, the goal is to reduce the global burden of TB and improve the lives of those affected by this serious infectious disease.